Kenji Okita

Otaru, 0470032, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 78 publications

Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone.

Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone.

Journal: International journal of clinical oncology

Published: April 12, 2026

Safety and efficacy of a 12-mm trocar with integrated fascial closure for preventing port-site hernia in minimally invasive abdominal surgery: a multicenter prospective observational study among over weight patients with thick abdominal walls.

Safety and efficacy of a 12-mm trocar with integrated fascial closure for preventing port-site hernia in minimally invasive abdominal surgery: a multicenter prospective observational study among over weight patients with thick abdominal walls.

Journal: Surgical endoscopy

Published: July 17, 2025

Patient-related risk factors for outlet obstruction in diverting loop ileostomy following minimally invasive rectal cancer surgery.

Patient-related risk factors for outlet obstruction in diverting loop ileostomy following minimally invasive rectal cancer surgery.

Journal: Techniques in coloproctology

Published: July 03, 2025

Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy.

Real-world adherence to antiemetic guidelines in Japanese patients receiving high or carboplatin-based moderate emetic risk chemotherapy.

Journal: International journal of clinical oncology

Published: May 29, 2025

Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.

Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.

Journal: International journal of clinical oncology

Published: September 25, 2024

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.

Journal: International journal of clinical oncology

Published: August 01, 2024

Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.

Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.

Journal: International journal of clinical oncology

Published: July 26, 2024

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.

Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.

Journal: International journal of clinical oncology

Published: July 17, 2024

ctDNA-based molecular residual disease and survival in resectable colorectal cancer.

ctDNA-based molecular residual disease and survival in resectable colorectal cancer.

Journal: Nature medicine

Published: July 15, 2024

Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Journal: International journal of clinical oncology

Published: July 11, 2024

Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.

Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023.

Journal: International journal of clinical oncology

Published: March 25, 2024

2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.

2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis.

Journal: International journal of clinical oncology

Published: February 27, 2024

Showing 1-12 of 78

Last Updated: 09/26/2026